A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
NCT ID: NCT04973111
Last Updated: 2025-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
2021-07-16
2022-04-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
NCT00882726
Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)
NCT01106287
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
NCT01301456
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
NCT00478322
Therapeutic Exploratory Study of CWP-0403
NCT00888719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CT-868
SC dose of CT-868 Intervention: Drug: CT-868
CT-868 as SC Injection
CT-868
Placebo
SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo
Placebo as SC Injection
Placebo
Active Comparator
SC dose of Active Comparator Intervention: Drug: Active Comparator
Active Comparator as SC Injection
Active Comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT-868 as SC Injection
CT-868
Placebo as SC Injection
Placebo
Active Comparator as SC Injection
Active Comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Part 2: Males or Females with T2D
* Part 1: BMI 30.0-35.0, inclusive
* Part 2: BMI 27.0-45.0, inclusive
* 18-65 years old, inclusive
* Stable body weight for 2 months
Exclusion Criteria
* Uncontrolled hypertension
* History of malignancy
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carmot Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Carmot Therapeutics, Inc., a member of the Roche Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmot Clinical Research Unit 101
Chula Vista, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT-868-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.